Mubadala Investment Co PJSC - Dec 23, 2022 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
10%+ Owner
Signature
/s/ Samer Halawa, Chief Legal Officer, Mubadala Investment Company PJSC (17)
Stock symbol
RXRX
Transactions as of
Dec 23, 2022
Transactions value $
$7,725,857
Form type
4
Date filed
1/13/2023, 03:19 PM
Previous filing
Oct 31, 2022
Next filing
Jan 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Purchase $754K +100K +0.89% $7.52 11.4M Dec 23, 2022 See Explanation of Responses F1, F2, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $1.05M +146K +1.28% $7.24 11.5M Dec 27, 2022 See Explanation of Responses F1, F3, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $512K +71.3K +0.62% $7.18 11.6M Dec 28, 2022 See Explanation of Responses F1, F4, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $653K +84.6K +0.73% $7.71 11.7M Dec 29, 2022 See Explanation of Responses F1, F5, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $754K +99.8K +0.85% $7.55 11.8M Dec 30, 2022 See Explanation of Responses F1, F6, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $1.06M +142K +1.2% $7.50 11.9M Jan 3, 2023 See Explanation of Responses F1, F7, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $717K +91.9K +0.77% $7.80 12M Jan 4, 2023 See Explanation of Responses F1, F8, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $591K +80K +0.67% $7.38 12.1M Jan 5, 2023 See Explanation of Responses F1, F9, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $511K +69K +0.57% $7.41 12.2M Jan 6, 2023 See Explanation of Responses F1, F10, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $581K +76K +0.62% $7.64 12.3M Jan 9, 2023 See Explanation of Responses F1, F11, F13, F15, F16
transaction RXRX Class A Common Stock Purchase $537K +69.5K +0.57% $7.72 12.3M Jan 10, 2023 See Explanation of Responses F1, F12, F13, F15, F16
holding RXRX Class A Common Stock 7.06M Dec 23, 2022 See Explanation of Responses F14, F15, F16
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This is an inadvertent late filing due to an administrative error.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.70, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (12) to this Form4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.12 to $7.61, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.07 to $7.32, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.25 to $7.91, inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.33 to $7.72, inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.37 to $7.83, inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $7.88, inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.30 to $7.75, inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.10 to $8.00, inclusive.
F11 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.43 to $8.00, inclusive.
F12 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.52 to $8.00, inclusive.
F13 Consists of 12,321,732 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.
F14 MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
F15 Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
F16 Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

17. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.